In 2001, Andreassi et al. showed that aclarubicin, an anthracycline anticancer drug, blocked SMN2 gene exon 7 skipping in fibroblasts from patients with SMA [113]. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.